DOI: 10.1055/s-00000020

Geburtshilfe und Frauenheilkunde


Turner NC, Telli ML, Rugo HS. et al.
Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO).

J Clin Oncol 2017;
35 (Suppl.) Abstr.. 1007

Download Bibliographical Data

Search in: